Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of telotristat etiprate in inadequately controlled carcinoid syndrome
2012-003460-47Phase 3Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Carcinoid Syndrome (CS) comparing Telotristat etiprate with Placebo (2 arms). Primary endpoint: Change from baseline in daily bowel movements over 12 weeks. Started Nov 2012; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on 2012-003460-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003460-47.